Data Consortiums: Answering Tomorrow’s Questions Today

Diana Brixner, PhD
University of Utah College of Pharmacy

Organizations may not re-use material presented at this AMCP conference for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use material presented at [conference] without the written consent of the presenter the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.
Data Consortiums: Answering Tomorrow’s Questions Today

Diana Brixner, PhD
Professor and Chair, Department of Pharmacotherapy,
Executive Director of the Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
Data Consortiums Promise

Vision: High-Value Care
Driven by Rapidly Improving Science

Source: IOM, 2012
Trends Driving Consortiums

• American Recovery & Reinvestment Act, and Meaningful Use goals, especially monitoring population health measures

• ACA mandate to cover conditions of shared concern by HC and PHS systems and national strategy for quality improvement in health care

• Prevalence of chronic diseases

• Successes of public–private partnerships
  – Interagency Registry for Mechanically Assisted Circulatory Support—INTERMACS
  – Simulations carried out by the HMO Research Network demonstrating how their “virtual database” would have detected Vioxx ADE within months
Consortiums Versus Databases

Consortiums avoid the creation of large, static data bases susceptible to leaks or tampering

- “Virtual Data Networks” or” Distributed Data Networks”
- NHDSE—AHRQ proposed National Health Data Stewardship Entity which would
  - act as a data repository and manager
  - possess policy making, data governance and stewardship functions
  - advising public agencies in standard-setting
    - regarding the acquisition, management, and use of health information, as well as on priority matters
- Public comment on NHDSE proposal:
  - Concerns around role being given to public versus existing private vendors
  - Few comment on structure and governance (e.g., advisory committee) and public records
Data Consortiums: AHRQ Prototype
Types of Data Consortia-Terms

• Data stewardship
  – denotes an approach to the management of data, particularly data that can identify individuals.
  – management methods covering acquisition, storage, aggregation, and de-identification, and procedures for data release and use
  – conveys a fiduciary (or trust) level of responsibility toward the data.

• Data governance
  – process by which responsibilities of stewardship are conceptualized and carried out.
  – Policies and approaches that allow stewardship
  – Establishes qualifications of users

• Health services research-twin assumptions
  – good evidence can be created from health care data on patients, providers, and health care systems
  – The data will be available
Types of Data Consortiums-Owners

• Types of owners:
  – Individual investigators
  – Health care providers (e.g., MCO)
  – Government sponsored
  – Public–private partnerships

• Data ownership versus data access. Owners can give access to multiple research organizations

• Government role: monetizing vs. stewardship:
  – Stewardship chosen with ACA: supports goals set by advocates of evidence-driven care (although subject to important limitations on the use of data.)

• Issues beyond ownership
  – We have the mechanisms to manage research in safe and secure environments—now the social and legal frameworks need to catch
Data Consortium Components

Data consortium components:

– System design to transmit aggregate data to a central repository
– Data-processing software
– Selection of statistical techniques and parameters
– Automated alerting.

Data linkage requires

– expertise in several areas, including knowledge of the datasets to be linked—at their limitations and idiosyncrasies
– skills in the use of linkage programs
– skills in statistical analysis and interpretation that comes from a multidisciplinary team including database managers and programmers
– statisticians work collaboratively with health services researchers to resolve technical problems while keeping eye on the research question.
– iterative cycles of assessment within and between sites
– constant communication between site-level data providers, data coordinating centers, and principal investigators.
Data Consortium Components-Data

Data must yield reliable and consistent results

- This requires careful definition of data elements and hypothesis statement before the research begins
- More data is better? Always able to simplify later?
- Data consistency is needed across the consortium, to allow independent researchers to validate the results
- Complete and accurate records on data collection are required
- Data complexity and inconsistency/non-comparability
- Need for markers/predictors of outcomes
- Investigate types and degree of missing data (e.g., attrition, nonresponse, non-coverage)
- Investigate miscoding
Outcomes Assessments That Data Consortiums Need To Access

ISPOR defines outcome assessments:

– All-cause mortality/survival

– Patient reported outcomes

– Clinician reported outcomes

  • Performance measures – six minute walk test, FEV1

  • Readings – liver/spleen size, swollen joints

  • Ratings – positive and negative signs and symptoms (PANSS) scale; switching interventions

– Observer reported outcomes

– Biomarkers

Outcomes measurement supports CER and HTA objectives
Data Consortiums: ADE Surveillance

• Data consortiums are well-positioned for adverse drug event surveillance
  – FDA risk evaluation and management ETASU documentation
  – HHS National Action Plan for Adverse Drug Event (ADE) Prevention for opioids, diabetic drugs, anticoagulants
  – Potential for real-time surveillance that provides comprehensive patient information to share among health care providers, health plans, MCOs, and PBMs

• For ADE surveillance, data consortiums need to include
  – Standardized signs and symptom measures (e.g., the critical path PRO consortium (http://www.C-path.Org/)
  – Laboratory Results and Biomarkers
Data consortium issues

– Selecting of appropriate data partners and developing trust between data partners and users
– Developing and refining statistical analyses and methods (e.g., Ensuring consistency across the data sources)
– Patient privacy
– Valid statistical approaches, for example:
  • Space-time scan statistic (to account for naturally occurring temporal and geographic trends)
  • Risk adjustments, selection bias, over-adjustment bias versus unnecessary adjustment
  • Propensity scores/adjustment for observables, longitudinal analysis/individual effects, instrumental variables
  • Cluster randomization, policy comparisons (instrumental variables)
• Concerns about potential liability under a host of civil and criminal laws, as well as on their competitive market position.
• Concerns about shielding information that may carry business, legal, or social costs.

Are these concerns valid?
• Most common legal cases are for providers who resisted releasing health data to their own patients out of liability concerns
• Shielding information from patients or failing to make use of information carries liability risks of its own (Institute of Medicine 2001)
• Under ACA, government has the power to establish a data steward (Federal Coordinating Council for Comparative Effectiveness Research)
Data Consortiums: MCO

• Research characteristics that may discourage MCO engagement in a consortium
  – Benefits (premiums, deductibles, copays)
  – Payments and service agreements
  – Networks
Data Consortiums: Mini-Sentinel Example

- Mini-Sentinel
- Data partners to maintain physical and operational control over the electronic data within their existing environments
- Common Data Model for Surveillance Activities
  - Allows MCO to protect patient privacy
  - MCOs run queries within their unique data system
  - Sample output
    - Calculating incidence rates
    - Protocol based assessments of medical products
  - How many patients taking olmesartan had developed celiac disease compared to those taking other similar drugs for high blood pressure?
- The methods and infrastructure established to support Sentinel present a valuable platform for developing a shared national resource

www.amcpfoundation.org
FDA Sentinel Initiative: Mini-Sentinel’s Distributed Database

1- User creates and submits query (a computer program)
2- Data partners retrieve query
3- Data partners review and run query against their local data
4- Data partners review results
5- Data partners return results via secure network
6- Results are aggregated
Data Consortiums: HMORN Example

- HMO Research Network (HMORN) is a consortium of 16 dedicated research centers based in non-profit health care systems. Its purpose is to foster collaborative research and knowledge sharing to improve health and health care for people nationally and globally.
- “Virtual Data Warehouse” or distributed data network
- NIH-HMO Collaboratory to support large scale epidemiologic and pragmatic clinical investigations across a range of diseases and health conditions. Source of investment is the NIH Common Fund
- CDC-supported surveillance projects: maternal morbidity, AMLS registry, vaccine surveillance, PID, TB and tuberculosis, and bioterrorism syndromes
- Structure: Governing Board and Asset Stewardship Committee.
  - Considering Executive Committee that could be more nimble and responsive, create strategy, and manage growth.
Data Consortiums: NDP Example

- The National Demonstration Bioterrorism Surveillance program (NDP) is used for detecting unusual clusters of disease and reducing alert levels.
- A distributed data processing approach where highly aggregated count data is transferred for statistical processing using “first encounter” methodology.
Data Consortiums: OMOP Example

- Why: researchers were always hampered by a reliance on voluntary reporting for ADE.
- 2007 Congress authorized FDA to initiate drug surveillance programs.
- OMOP (Observational Medical Outcomes Partnership)
  - In partnership with PhRMA and the FDA, the Foundation for the National Institutes of Health launched a public-private partnership.
  - Broad aim broader aims: identifying the most reliable methods for analyzing huge volumes of data drawn from heterogeneous sources.
- OMOP Common Framework (Common Data Model and Vocabulary Specifications)
  - Continues to be used for building observational networks in CER and safety research.
- OMOP Web Research Lab (Web RL) Cloud Provisioning Platform Software.
  - In public domain to build cloud-based data management and computationally rich computing environments.
  - http://omop.fnih.org/

www.amcpfoundation.org
Biosimilar Collective Intelligence System: Utilizing Data Consortia to Prove the Safety and Effectiveness of Biosimilars

- Biosimilars represent an opportunity to bend the cost curve for specialty drugs.
- Will explore the feasibility of launching a Biosimilars Collective Intelligence System to document the safety and efficacy of biosimilars, with reference to the data available for the innovator specialty drug.
- Goal is to have a Biosimilars Collective Intelligence system up and running before the first biosimilars hits the market.
- Data consortium and specialty drug experts from the leading US managed care organizations will lend their expertise to identifying the action steps.
- Also engaging health services researchers including the Harvard Mini-sentinel group; governmental agencies including FDA, AHRQ, and PCORI; PBMs and specialty management organizations; the Brookings Institute; and pharmaceutical manufacturers.
Caveats for Data Consortiums for CER

- EHRs may Contain Inaccurate (or Incorrect) Data
- EHRs Often do not Tell a Complete Patient Story
- Many of the Data Have Been Transformed/Coded for Purposes Other Than Research and Clinical Care
- Data Captured in Clinical Notes (Text) may not be Recoverable for CER
- EHRs may Present Multiple Sources of Data That Affect Data Provenance
- Data Granularity in EHRs may not Match the Needs of CER
- There are Differences Between Research Protocols and Clinical Care

Med Care 2013;51: S30–S37
• Scalable National Network for Effectiveness Research (SCANNER)—develop infrastructure consistent with privacy and security laws and best practices. (Along with EDM and PCORI)

• policies depend on
  – data type (aggregate counts, deidentified, limited, and fully identified datasets)
  – flow of data

• Possible requirements
  – Network agreement
  – Data use agreement
  – Authentication of users
  – Audit
  – IRB protocol
  – Identified data screening
  – Tagging data as sensitive

*Med Care* 2013;51: S66–S72